Want to see HK:2327 full AI Analyst Report?
2327 Stock Chart & Stats
HK$0.28
-HK$0.01(-3.39%)
At close: 4:00 PM EST
HK$0.28
-HK$0.01(-3.39%)
Day’s Range― - ―
52-Week RangeHK$0.21 - HK$0.31
Previous CloseN/A
Volume54.00K
Average Volume (3M)3.52M
Market Cap
HK$1.01B
Enterprise ValueHK$1.39B
Total Cash (Recent Filing)HK$20.18M
Total Debt (Recent Filing)HK$380.96M
Price to Earnings (P/E)26.8
Beta0.26
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2%
Share Statistics
EPS (TTM)<0.01
Shares Outstanding4,060,684,600
10 Day Avg. Volume6,054,000
30 Day Avg. Volume3,517,820
Financial Highlights & Ratios
PEG Ratio1.61
Price to Book (P/B)0.87
Price to Sales (P/S)29.64
P/FCF Ratio-21.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained gross margins around 57–62% indicate durable product-level profitability and pricing power. This margin buffer supports coverage of SG&A and restructuring costs, enabling the company to invest in strategic initiatives and preserve cash cushion even if top-line recovery is gradual.
Moderate Leverage / Stable Balance SheetDebt-to-equity in the ~0.19–0.31 range and sizable equity give financial flexibility. Moderate leverage reduces refinancing and solvency risk, allowing the company to withstand operating volatility, access funding if needed, and prioritize investment or restructuring without imminent balance-sheet stress.
Strong Headline Net Income MarginsVery strong reported net margins have generated retained earnings and potentially extra capital to deploy. While part of these margins may reflect non-operating items, sustained high net income provides a balance-sheet buffer for strategic moves, debt servicing and funding near-term recovery efforts.
Bears Say
Operating Performance DeteriorationA ~-30% EBIT margin in 2025 signals core business deterioration: revenue declines and operating losses undermine long-term profitability. Persistent operating weakness limits sustainable earnings, risks eroding competitive position, and makes recovery dependent on structural changes rather than cyclical rebound.
Volatile And Weak Cash GenerationOperating and free cash flow flipping negative introduces funding and liquidity risk. Volatile cash conversion reduces ability to self-fund capex, working capital and dividends, increases reliance on external financing, and raises the chance that reported profits do not translate into sustainable cash returns.
Declining Revenue TrendMaterial revenue decline (nearly -28% growth) reduces operating leverage and makes fixed costs harder to absorb. Shrinking top-line undermines long-term margin sustainability and market position, forcing cost cuts or strategic shifts that may impair growth prospects and the ability to restore stable operating performance.
Meilleure Health International Industry Group Limited News
2327 FAQ
What was Meilleure Health International Industry Group Limited’s price range in the past 12 months?
Meilleure Health International Industry Group Limited lowest stock price was HK$0.21 and its highest was HK$0.31 in the past 12 months.
What is Meilleure Health International Industry Group Limited’s market cap?
Meilleure Health International Industry Group Limited’s market cap is HK$1.01B.
When is Meilleure Health International Industry Group Limited’s upcoming earnings report date?
Meilleure Health International Industry Group Limited’s upcoming earnings report date is Aug 27, 2026 which is in 52 days.
How were Meilleure Health International Industry Group Limited’s earnings last quarter?
Meilleure Health International Industry Group Limited released its earnings results on Mar 27, 2026. The company reported HK$0.006 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.006.
Is Meilleure Health International Industry Group Limited overvalued?
According to Wall Street analysts Meilleure Health International Industry Group Limited’s price is currently Overvalued.
Does Meilleure Health International Industry Group Limited pay dividends?
Meilleure Health International Industry Group Limited pays a Notavailable dividend of HK$0.004 which represents an annual dividend yield of 2%. See more information on Meilleure Health International Industry Group Limited dividends here
What is Meilleure Health International Industry Group Limited’s EPS estimate?
Meilleure Health International Industry Group Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Meilleure Health International Industry Group Limited have?
Meilleure Health International Industry Group Limited has 4,060,684,600 shares outstanding.
What happened to Meilleure Health International Industry Group Limited’s price movement after its last earnings report?
Meilleure Health International Industry Group Limited reported an EPS of HK$0.006 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Meilleure Health International Industry Group Limited?
Currently, no hedge funds are holding shares in HK:2327
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Meilleure Health International Industry Group Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.57%
12-Months-Change
Fundamentals
Return on Equity
3.08%
Trailing 12-Months
Asset Growth
8.81%
Trailing 12-Months
Company Description
Meilleure Health International Industry Group Limited
Meilleure Health International Industry Group Limited functions as an investment holding company, overseeing a broad spectrum of ventures in Hong Kong, the People's Republic of China, and other international markets. Its diverse operations include industrial hemp, healthcare-related services, trading, various agency services, and both property investment/leasing and development. The company actively engages in the commerce of construction supplies, the creation and sale of residential real estate, property asset management, and the distribution of health-related goods. Furthermore, it provides real estate brokerage, services focused on the application of cannabidiol (CBD) derivatives, and comprehensive health management offerings, such as anti-aging treatments, aesthetic medicine, and general wellness consulting. It also acts as an agent for healthcare product sales. Formerly known as U-Home Group Holdings Limited, the company rebranded to Meilleure Health International Industry Group Limited in March 2017. Its primary corporate office is located in Admiralty, Hong Kong.
Meilleure Health International Industry Group Limited (2327) Earnings & Revenues
Technical Analysis
Xi'an Haitiantian Holdings Co
―
Chevalier International Holdings Limited
―
Aceso Life Science Group Limited
―
EPI (Holdings) Limited
―
Loco Hong Kong Holdings Ltd
―
Options Prices
Currently, No data available
---